Global Emerging Cancer Diagnostics Market Analysis & Forecast 2017-2023: Market Is Expected To Grow At A CAGR Of 13.45% and Reach $6.34 Billion - Research and Markets

DUBLIN, Apr 7, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2017-2023 (Focus on Biomarker Test Type, Application & Market Trends)" report to their offering.

The Global Emerging Cancer Diagnostics Market Is Expected To Grow At A CAGR Of 13.45% From 2016 To 2023 And Reach A Figure Of $6.34 Billion By 2023

Cancer is a chronic disease and is affecting a huge population. Many technologies are emerging in the cancer diagnostics market. This report is focused on emerging cancer diagnostics market specifically on biomarker tumor test. The market growth is propelled due to factors such as: increasing number of cancer cases, technological innovation and advancements, increasing awareness among people, and medicare & reimbursement policies, among others.

This study includes an overview and analysis of the emerging cancer diagnostics market, by test type, applications, and geography, allowing the research to develop a comprehensive outlook of the market. The market report presents a detailed and analytical study of the entire market and provides a comprehensive insight into various forms of developments, trends and key participants.

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, associations, and regulatory bodies, and their involvement in the emerging cancer diagnostics market.

The research study tries to answer various aspects of the emerging cancer diagnostics market with the help of central factors driving the market, threats that can possibly slow down the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study takes into account Porter's Five Force model and opportunity matrix for an in-depth study of the emerging cancer diagnostics market and an assessment of the factors governing the same.

Key Topics Covered:

Executive Summary

1 The Research Scope and Methodology
1.1 Scope of the Report
1.2 Global Emerging Cancer Diagnostics Market Research Methodology

2 Introduction to Global Emerging Cancer Diagnostics Market
2.1 Overview
2.2 Analysis of Lifestyle Factors
2.2.1 Obesity/Weight
2.2.2 Physical Activity
2.2.3 Food Habits
2.2.4 Alcohol & Cancer
2.2.4.1 Countries with Highest Consumption of Alcoholic Drinks
2.2.5 Salt Consumption
2.2.6 Breastfeeding
2.3 High and Low Developed Countries
2.4 Data for Cancer Frequency by Country
2.5 Worldwide Cancer Data

3 Market Dynamics
3.1 Market Drivers
3.1.1 Increase in Prevalence Rate of Cancer
3.1.2 Increase in Sedentary Lifestyles
3.1.3 Robust Technological Advancement
3.1.4 Environmental Hazards
3.1.4.1 Five Primary Categories of Carcinogens are: -
3.1.5 Government Initiatives and Investment
3.2 Market Challenges
3.2.1 High Capital Investment
3.2.2 Dearth of Skilled Professionals
3.2.3 Lack of Awareness
3.3 Market Opportunities
3.3.1 Nanotechnology Applications in Cancer
3.3.2 3D Printing in Cancer Diagnostics
3.3.3 Robotics in Cancer Diagnostics and Treatment
3.3.4 Fluid Biopsy
3.3.5 Real Time Cancer Diagnostic iKnife

4 Competitive Insights

5 Industry Analysis
5.1 Patent Analysis
5.2 Consortiums, Associations and Regulatory Bodies

6 Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market, Analysis and Forecast
6.1 Assumptions & Limitations for Analysis and Forecast
6.2 Market Overview
6.3 Global Emerging Cancer Diagnostics Market by Tumor Biomarker Test
6.3.1 Prostate Specific Antigen Tests
6.3.2 CTC Tests
6.3.3 Alpha-Fetoprotein (AFP) Tests
6.3.4 CA Test
6.3.5 HER2 Tests
6.3.6 BRCA Test
6.3.7 Anaplastic Lymphoma Kinase (ALK) Tests
6.3.8 EGFR Mutation Tests
6.3.9 KRAS Test
6.3.10 Others
6.3.10.1 National Rental Affordability Scheme (NRAS) Testing
6.3.10.2 RET Gene Testing
6.3.10.3 ROS Testing
6.3.10.4 PIK3CA Tests
6.4 Global Emerging Cancer Diagnostics Market by Application
6.4.1 Lung Cancer
6.4.2 Breast Cancer
6.4.3 Colorectal
6.4.4 Prostate Cancer
6.4.5 Blood Cancer
6.4.5.1 Leukaemia
6.4.5.2 Lymphoma
6.4.5.3 Myeloma
6.4.6 Others
6.5 Global Emerging Technologies in Cancer Diagnostics Market by Geography
6.5.1 North America
6.5.1.1 Country Analysis
6.5.1.1.1 U.S.
6.5.1.1.2 Canada
6.5.2 Europe
6.5.2.1 Countries Having the Highest Cancer Rates
6.5.3 APAC

7 Company Profiles

- Abbott Laboratories, Inc
- LabCorp Of America Holdings
- Luminex Corporation
- Myriad Genetics Inc
- NanoString Technologies Inc
- Neo Genomics Inc
- Quest Diagnostics Incorporated
- Qiagen, Inc
- Roche Holding AG-BR
- Siemens Healthineers
- Thermo Fisher Scientific
- Agilent Technologies
- Biotheranostics, Inc
- Almac group
- GeneNews Limited (formerly ChondroGene Limited)
- Rosetta Genomics
- Epigenomics
- Exact Sciences Corporation
- Ignyta,Inc
- Interpace Diagnostics
- Leica Biosystems
- BioTime, Inc
- Pathway Genomics
- Sysmex Corporation
- AstraZeneca
- Becton Dickinson & Co
- Biocept Inc
- Cancer Genetics Inc
- Danaher Corporation
- Foundation Medicine Inc
- Illumina Inc

For more information about this report visit http://www.researchandmarkets.com/research/6hr82h/global_emerging

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]